Partnering

NeuroSTAT – for treatment of traumatic brain injury

Traumatic brain injury (TBI) is caused by external force to the head resulting in immediate damage to nerve cells. The damage continues to worsen for several days after the acute trauma.

Treatment objective

The aim for NeuroSTAT, targeting the mitochondria, is to counteract the emergence of neurological and functional secondary brain damage after a traumatic injury, and thereby establish a therapy that will lead to increased survival, improved quality of life and preserved neurological function.

Project status: candidate drug in clinical Phase II

NeuroSTAT has shown favorable properties in a Phase Ib/IIa clinical study and in advanced experimental TBI models at the University of Pennsylvania (Penn). NeuroSTAT has orphan drug designation in Europe and the US as well as an IND approval and Fast Track designation for clinical development in the US.

Abliva is engaging in preliminary discussions with the TRACK-TBI network regarding a potential collaboration within the scope of the so called Precision Medicine project for a Phase II study on traumatic brain injury with NeuroSTAT. The study, if authorized by US Department of Defence (DOD), would commence in 2022, contingent upon DOD’s approval of earlier steps of the project.

The company will review possible options and structures that may enable developing the NeuroSTAT program further.

Primary mitochondrial disorders

Abliva is interested in partnering its innovative primary mitochondrial disorders portfolio to advance these programs as effectively as possible. The company can consider different partnering models, depending on what is optimal for our programs and partners.


BD Contact

CEO Ellen K. Donnelly

bd@abliva.com